Acasă › Mielom multiplu › District of Columbia › Washington
Studii clinice pentru Mielom multiplu în Washington, DC
22 studii pentru Mielom multiplu caută participanți în și în jurul orașului Washington (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
În curs de recrutareFaza 1
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
În curs de recrutareFaza 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
În curs de recrutareStudiu observațional
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
În curs de recrutareFaza 2
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
Tissue Collection for Studies of Lymph Cancer
În curs de recrutareStudiu observațional
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
În curs de recrutareFaza 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · La 7 mi distanță
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
În curs de recrutareFaza 3
- Center for Cancer and Blood Disorders, Bethesda · La 7 mi distanță
18F-Fluciclovine PET/CT in Multiple Myeloma
În curs de recrutareFaza 2
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
În curs de recrutareFaza 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · La 7 mi distanță
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
În curs de recrutareFaza 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
În curs de recrutareStudiu observațional
- National Institutes of Health Clinical Center, Bethesda · La 7 mi distanță
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
În curs de recrutareFaza 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
În curs de recrutareFaza 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
În curs de recrutareFaza 2
- GSK Investigational Site, Bethesda · La 7 mi distanță
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
În curs de recrutareFaza 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
În curs de recrutare
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · La 7 mi distanță
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
În curs de recrutareFaza 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · La 7 mi distanță
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
În curs de recrutareFaza 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
În curs de recrutareFaza 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
În curs de recrutareFaza 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Boston, MA42 studii
- Atlanta, GA42 studii
- Houston, TX38 studii
- Durham, NC37 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- St. Louis, MO24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Edison, NJ22 studii
Alte studii în Washington
- Cancer (toate tipurile)58 studii
- Cancer pulmonar cu celule non-pătrate55 studii
- Cancer de sân46 studii
- Cancer metastatic43 studii
- Cancer pulmonar41 studii
- Cancer de prostată38 studii
- Obezitate33 studii
- Cancer colorectal29 studii
- Boli cardiovasculare28 studii
- Cancer de vezică urinară26 studii
- Leucemie mieloasă acută24 studii
- Cancer ovarian23 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.